Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,409 across all filing types
Latest filing 2016-01-05 Report Publication Anno…
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Upcoming investor conferences
Report Publication Announcement Classification · 99% confidence The document is a short press release dated January 5, 2016, announcing the company's schedule for attending various upcoming investor conferences and events during Q1 2016. It does not contain detailed financial results (ruling out ER, IR, 10-K), nor is it a transcript (CT) or a formal regulatory filing like a DVA or DIRS. Since it is an announcement about the company's engagement with the financial community regarding future events, it most closely aligns with general Investor Relations communication. Given the provided options, this type of forward-looking announcement about investor engagement, which is not a specific report type (like IP or FS), falls best under the general category of Regulatory Filings (RNS) as a miscellaneous corporate communication, although it is primarily an investor relations update. However, since the content is purely about upcoming investor meetings and not a formal report publication announcement (RPA), RNS is the most appropriate fallback for this type of corporate news release that doesn't fit the other specific categories.
2016-01-05 English
Prochains rendez-vous investisseurs
Report Publication Announcement Classification · 99% confidence The document is titled "PROCHAINS RENDEZ-VOUS INVESTISSEURS" (Upcoming Investor Meetings) and lists several financial conferences the company (Innate Pharma) will attend in Q1 2016. It also directs investors to the company website for financial statements and investor presentations. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a specific regulatory filing like a Director's Dealing (DIRS) or Dividend Notice (DIV). It is an announcement informing investors about future engagement opportunities and where to find corporate information. This fits best under the category of general corporate/investor relations communication, which is often classified as a Regulatory Filing (RNS) if it doesn't fit a more specific investor-focused category like Investor Presentation (IP) or Earnings Release (ER). Since it is an announcement about future events rather than the release of a specific report, RNS is the most appropriate fallback, although it shares characteristics with an Investor Presentation announcement, it is primarily a schedule announcement.
2016-01-05 French
Communiqué du 17 décembre 2015
Regulatory Filings Classification · 95% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces the opening of a new clinical trial testing Monalizumab. It details the trial design, scientific rationale, and provides context about the disease and the drug. This type of announcement, detailing operational or scientific progress (like clinical trial initiation) via a press release, is typically classified as a general Regulatory Filing (RNS) or sometimes an Investor Presentation (IP) if it were a slide deck. However, given the format is a formal press release announcing a specific operational/clinical event, and it doesn't fit the definitions for ER (Earnings Release), CT (Call Transcript), or specific financial reports, RNS (Regulatory Filings / General regulatory announcements) is the most appropriate general category for this type of corporate disclosure that isn't a formal SEC/Exchange report like a 10-K or DEF 14A. The length (13,677 chars) suggests it is the full content, not just a brief announcement of a report (ruling out RPA).
2015-12-17 French
PR Dec. 17, 2015
Investor Presentation Classification · 95% confidence The document is a press release dated December 17, 2015, announcing the opening of a new clinical trial (Phase Ib/II) for the drug monalizumab in combination with cetuximab for head and neck cancer. It details the trial objectives, rationale, and context within the company's development plan and partnership with AstraZeneca. This type of announcement, detailing operational progress, clinical updates, and strategic partnerships, is characteristic of an Investor Presentation (IP) or a general press release regarding business operations. Since it is a detailed update on clinical development and strategy, 'Investor Presentation' (IP) is the most fitting category, as it provides substantial information intended for investors beyond just the basic financial highlights of an Earnings Release (ER). It is not a formal regulatory filing like a 10-K, an Audit Report (AR), or a simple Dividend Notice (DIV). Given the depth of clinical and partnership detail, IP is preferred over the general 'RNS' fallback.
2015-12-17 English
IPH Number of shares and voting rights
Share Issue/Capital Change Classification · 95% confidence The document explicitly states its purpose: 'NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT DECEMBER 7, 2015'. It cites French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter) requiring the disclosure of total shares outstanding and voting rights. This type of mandatory disclosure regarding share capital structure and voting power, especially when triggered by specific dates or thresholds, is a form of regulatory announcement. While it is a specific disclosure, it doesn't fit perfectly into the defined categories like DIV (dividend), SHA (share issue), or POS (transaction in own shares). Since it is a mandatory, specific regulatory disclosure that doesn't match a more precise category, the most appropriate fallback is Regulatory Filings (RNS), as it is a formal announcement to the market based on regulatory requirements.
2015-12-09 English
IPH Nombre d'actions et droits de vote
Share Issue/Capital Change Classification · 98% confidence The document is a formal announcement dated December 9, 2015, titled 'NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 7 DÉCEMBRE 2015' (New number of shares and voting rights of Innate Pharma as of December 7, 2015). It explicitly cites French regulatory articles (Code de Commerce and AMF regulations) regarding the publication of the total number of shares and voting rights. This content directly relates to changes in the company's capital structure and shareholder voting basis. This aligns perfectly with the 'Share Issue/Capital Change' definition (SHA), which covers capital structure changes, or potentially 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Since the core purpose is reporting the current share count and voting rights calculation basis (theoretical vs. exercisable), SHA is the most precise fit for a capital structure update notification, although DVA is also relevant for voting rights. Given the focus on the total share count ('Nombre d'actions composant le capital'), SHA is selected as the primary classification.
2015-12-09 French

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.